Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Sinaiko

Urology Bristol, PA Medical Doctor

NPI 1306827753 CMS profile 456583

501 Bath Rd, Ste 208, Bristol, PA 19007

Open in the dashboard

General payments

$2,871

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Sinaiko of Bristol, PA is reported in the CMS Open Payments database as having received $2,871 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 6
2024 General $232 6
2023 General $224 11
2022 General $1,107 21
2021 General $420 22
2020 General $323 16
2019 General $367 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Sinaiko
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Peter Sinaiko were reported at $198. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Peter Sinaiko Urology median Middle half National median
2019 $367 $480 $147–$1,201 $163
2020 $323 $246 $87–$645 $114
2021 $420 $358 $111–$1,000 $132
2022 $1,107 $476 $143–$1,263 $149
2023 $224 $560 $168–$1,461 $160
2024 $232 $563 $170–$1,464 $164
2025 $198 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,104 47 payments
  2. C. R. Bard, Inc. & Subsidiaries $684 1 payment
  3. Urovant Sciences Inc $213 10 payments
  4. Medtronic USA, Inc. $141 1 payment
  5. Sumitomo Pharma America, Inc. $113 5 payments
  6. Amgen Inc. $74 4 payments
  7. Braintree Laboratories, Inc. $73 1 payment
  8. Janssen Biotech, Inc. $68 4 payments
  9. Pfizer Inc. $57 4 payments
  10. Zyla Life Sciences $54 4 payments
  11. Other $291 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,903 94 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $684 1 payment
  3. Education $284 4 payments
Products named General payments · program years 2019–2025
  1. XTANDI $787 41 payments
  2. GEMTESA $326 15 payments
  3. INTERSTIM $141 1 payment
  4. MYRBETRIQ $135 9 payments
  5. XGEVA $74 4 payments
  6. SUFLAVE $73 1 payment
  7. SPRIX $54 4 payments
  8. ERLEADA $48 3 payments
  9. LUPRON DEPOT $39 3 payments
  10. ORGOVYX $36 3 payments
  11. Other $402 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

662

Median for Urology: 1,053

Drug cost

$536,862

Median for Urology: $101,464

Branded share of claims

32.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 32 $466,349
Myrbetriq Mirabegron Brand 44 $39,081
Potassium Citrate Er Potassium Citrate Brand 65 $13,921
Tamsulosin Hcl Generic 188 $4,128
Dutasteride-Tamsulosin Dutasteride/Tamsulosin Hcl Brand 15 $3,946
Rapaflo Silodosin Brand 13 $3,322
Dutasteride Generic 31 $1,859
Testosterone Cypionate Generic 27 $1,137
Finasteride Generic 46 $909
Allopurinol Generic 40 $513

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$26,797

Medicare's payments for the services billed

Medicare patients

140

Average age 76

Services billed

438

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 40%
Cancer 31%
Diabetes 30%
Chronic kidney disease 29%
Atrial fibrillation 20%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $155
$155 32 —
GEMTESA
  • Sumitomo Pharma America, Inc. $42
$42 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record